Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Protalix Biotherapeutics Inc V.PLX.H


Primary Symbol: PLX

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.


NYSEAM:PLX - Post by User

Comment by stockfyon May 05, 2018 9:36am
202 Views
Post# 27986787

RE:News

RE:NewsGreat deal! Deal closed. They paid a very low price because the seller had gone broke:


CALGARY, Alberta, May 01, 2018 (GLOBE NEWSWIRE) -- Point Loma Resources Ltd. (TSX VENTURE:PLX) is pleased to announce that it has acquired certain oil and gas assets from a private oil and gas company involved in a receivership process, with an effective date of November 1, 2017.

After closing adjustments, the net purchase price of the Acquisition was approximately $779,000 for Point Loma’s 70 percent working interest share. 

Highlights (figures gross unless stated otherwise):

  • Point Loma (70 percent working interest) and Salt Bush Energy Ltd. (“Salt Bush”) have acquired assets concentrated in the west central area of Alberta contiguous to Point Loma’s existing area of focus. 
     
  • Production of approximately 450 boe/d (315 boe/d net), comprised of 35 percent oil and ngl’s. 
     
  • Approximately 29,000 acres (12,900 net acres) of undeveloped land and over 130 kilometers of proprietary seismic in Point Loma’s core area of west central Alberta.   
     
  • The Acquisition had total proved reserves of 2.6 MMboe (1.9 MMboe net) and total proved reserve net present value, discounted at 10 percent, of $8.9 million ($6.2 million net). 
     
  • The Acquisition had estimated net operating income of $850,000 ($595,000 net) during the recent six month adjustment period (November 2017 – April 2018). 
     
  • The Acquisition has a liability management ratio (“LMR”) of 3.4, comprised of deemed assets of $11.5 million and deemed liabilities of $3.4 million.
 

The properties include areas with proved undeveloped locations booked in addition to the base production. Full summary tables of the reserves of the Acquisition were released in Point Loma’s March 19, 2018 press release.

 


<< Previous
Bullboard Posts
Next >>